BioSpace News Archive

NorthX Biologics announced today the successful acquisition of the Stockholm-based Clinical Trial Manufacturing unit from Valneva Sweden, significantly expanding capabilities.

DiaCarta, Ltd. today announced the termination of its Business Combination Agreement with HH&L Acquisition Co.

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2023 on Thursday, July 27, 2023, before the U.S. financial markets open.

Sarepta Therapeutics, Inc. today announced that senior management will participate in a fireside chat at Cowen’s 2nd Annual RNA Therapeutics Summit on Monday, July 10, 2023 at 11:00 a.m. E.T.

Centers for Medicare and Medicaid Services Accepts Myomo’s Application to Classify the MyoPro ® as a Brace.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that YUSIMRY™ (adalimumab-aqvh) is now available for commercial sale in the United States.

Soaak Technologies has announced its acquisition of RenuYou Clinics, a prestigious fifteen-year-old Board Certified clinic, specializing in a wide range of personalized therapies, including brain mapping and neurofeedback.

Topline results from the TROPION-Lung01 phase 3 trial showed datopotamab deruxtecan demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior therapy.

XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO’s conference call regarding the presentation of the interim report April-June 2023.

The IMPAHCT event, organized by the pharmaceutical company Ferrer, has brought together more than 150 pulmonologists and cardiologists from over 30 countries, consolidating the company’s commitment to the advancement of the research and treatment of pulmonary hypertension.